# A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

> **NCT00206167** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1600 (—)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Budesonide/formoterol pMDI
- **DRUG:** Formoterol Turbuhaler

## Key facts

- **NCT ID:** NCT00206167
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 1600 (—)
- **Last updated:** 2009-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206167, "A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00206167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*